title: Five years treatment outcomes of postoperative radiotherapy in saudi women with uterine cancers: single institutional experience.
abstract: We aimed to evaluate long-term treatment outcomes and toxicity profile of postoperative radiotherapy (PORT) in Saudi women with uterine cancers.
  
  
  METHODS
  Medical records of patients with histopathologically proven uterine cancers were reviewed and identified those who received PORT (45-50.4 Gy in 25-28 fractions) followed by vaginal brachytherapy (15-20 Gy in 3 to 4 sessions) after total abdominal hystrectomy and bilateral salpingo-oophorectomy (TAHBSO) in our center between August 2007 and April 2012. Data regarding the safety profile, locoregional control (LRC) or distant metastases control (DMC) and overall survival (OS) rates were analyzed.
  
  
  RESULTS
  Median follow-up period was 60 months (range, 12-70) for 89 patients. Predominant histological type was endometrial (59 patients), followed by carcinosarcoma (17 patients) and leiomyosarcoma (13 patients). Median age at time of diagnosis was 57.6, 56 and 51.1 years for endometrial, carcinosarcoma and leiomyosarcoma respectively. LRC rates were 80.9%, 87.1% and 100% for leiomyosarcoma, carcinosarcoma and endometrial carcinoma respectively (p 0.4). DMC rates were 69.3%, 45% and 16.3% for endometrial, leiomyosarcoma and carcinosarcoma respectively (p 0.0001). Five-year OS rates were 71.1%, 60% and 16.3% for endometrial, leiomyosarcoma and carcinosarcoma respectively (p 0.001). Coxproportional hazard ratio model showed body mass index, FIGO stage, lymphovascular invasion in endometrial carcinoma, tumor size in leiomyosarcoma and histology in carcinosarcoma important prognostic factors for LRC. Acute grade 3 and 4 proctitis/enteritis seen only in 4 patients (4.5%) and late toxicities were minimal.
  
  
  CONCLUSIONS
  PORT in Saudi women with uterine cancers showed better LRC, DMC and OS rates with minimal toxicity.
authors.affiliation: Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 59046, Saudi Arabia.
authors.forename: M
authors.initials: M
authors.lastname: Al Asiri
authors.affiliation: Mutahir Tunio, MBBS, FCPS (Radiation Oncology), Assistant Consultant, Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 59046, Saudi Arabia, Tel: +966 1 2889999 Fax: 966 1 4614006. Email: drmutahirtonio@hotmail.com.
authors.forename: M A
authors.initials: MA
authors.lastname: Tunio
authors.affiliation: Radiation Oncology, National Cancer Institute, Cairo University, Cairo-Egypt.
authors.forename: Y
authors.initials: Y
authors.lastname: Bayoumi
authors.affiliation: Radiation Oncology, National Cancer Institute, Cairo University, Cairo-Egypt.
authors.forename: R
authors.initials: R
authors.lastname: Mohamed
authors.affiliation: Radiation Oncology, King Khalid University Hospital, Riyadh, Saudi Arabia.
authors.forename: E
authors.initials: E
authors.lastname: Al Saeed
authors.affiliation: Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 59046, Saudi Arabia.
authors.forename: A
authors.initials: A
authors.lastname: Al Hadab
authors.affiliation: Radiation Oncology, Comprehensive Cancer Center, King Fahad Medical City, Riyadh 59046, Saudi Arabia.
authors.forename: A
authors.initials: A
authors.lastname: Al Amro